Pharmacologic treatment of heart failure due to ventricular dysfunction by myocardial stunning: Potential role of levosimendan

American Journal of Cardiovascular Drugs

Volumn 6, Issue 2, 2006, Pages 69-75

  García González, Martín J ^a   Domínguez Rodríguez, Alberto ^a  

^a HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; AMRINONE; APRIKALIM; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM SENSITIZER; CAPTOPRIL; CARDIOVASCULAR AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; DOPAMINE; ENDOTHELIN RECEPTOR ANTAGONIST; FELODIPINE; GLIBENCLAMIDE; INOTROPIC AGENT; ITRACONAZOLE; LEVOSIMENDAN; MILRINONE; N [4 (1,4,5,6 TETRAHYDRO 4 METHYL 6 OXO 3 PYRIDAZINYL)PHENYL]ACETAMIDE; NITRIC OXIDE DONOR; PHOSPHODIESTERASE INHIBITOR; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL STIMULATING AGENT; PRIMOBENDAN; PYRIDAZINONE DERIVATIVE; SIMENDAN; SULMAZOLE; TOLBUTAMIDE; TRIMETAZIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; ACUTE HEART FAILURE; ALKALINE PHOSPHATASE BLOOD LEVEL; CALCIUM CELL LEVEL; CARDIOGENIC SHOCK; CELL FUNCTION; CLINICAL TRIAL; CORONARY ARTERY DILATATION; CREATININE BLOOD LEVEL; CYTOSOL; DRUG EFFICACY; ENERGY CONSUMPTION; HEADACHE; HEART ARRHYTHMIA; HEART DISEASE; HEART FAILURE; HEART HEMODYNAMICS; HEART INFARCTION; HEART MUSCLE; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART MUSCLE OXYGEN CONSUMPTION; HEART PROTECTION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FAILURE; HEART VENTRICLE OVERLOAD; HUMAN; HYPOTENSION; INFLAMMATION; MORBIDITY; MORTALITY; MYOFILAMENT; NAUSEA; NONHUMAN; PATHOPHYSIOLOGY; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BINDING; PROTEIN FUNCTION; REPERFUSION INJURY; REVIEW; SENSITIVITY ANALYSIS; SINUS TACHYCARDIA; ST SEGMENT ELEVATION; STUNNED HEART MUSCLE; TREATMENT OUTCOME; VOMITING;

ADENOSINE TRIPHOSPHATE; CARDIOTONIC AGENTS; HEART FAILURE, CONGESTIVE; HUMANS; HYDRAZONES; MODELS, BIOLOGICAL; MYOCARDIAL STUNNING; POTASSIUM CHANNELS; PYRIDAZINES; RANDOMIZED CONTROLLED TRIALS; VENTRICULAR DYSFUNCTION;

EID: 33645222594     PISSN: 11753277     EISSN: 11753277     Source Type: Journal    
DOI: 10.2165/00129784-200606020-00001     Document Type: Review

References (47)

1. Remme WJ, Swedberg K. Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology: guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001; 22: 1527-60
2. Heyndrickx GR, Millard RW, McRitchie RJ, et al. Regional myocardial functional and electrophysiological alterations after a brief coronary artery occlusion in conscious dogs. J Clin Invest 1975; 56: 978-95
3. Braunwald E, Kloner RA. The stunned myocardium: prolonged postischemic ventricular dysfunction. Circulation 1982; 66: 1146-9
4. Bolli R, Marban E. Molecular and cellular mechanisms of myocardial stunning. Physiol Rev 1999; 79: 609-34
5. Mann DL, Young JB. Basic mechanisms in congestive heart failure: recognizing the role of proinflammatory cytokines. Chest 1994; 105: 897-904
6. Adamopoulos S, Parissis JT, Kremastinos DT. A glossary of circulating cytokines in chronic heart failure. Eur J Heart Fail 2001; 3: 517-26
7. Meldrum DR, Meng X, Dinarello CA, et al. Human myocardial tissue TNF-α expression following acute global ischemia in vivo. J Mol Cell Cardiol 1998; 30: 1683-9
8. + channels and their role in cardioprotection. Circ Res 2004; 94: 420-32
9. + channel in cardiac function and cardioprotection. Biochim Biophys Acta 2003; 1606: 1-21
10. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525-33
11. Manito N, Kaplinsky EJ, Pujol R. Inotropic therapy in heart failure: general aspects and clinical results [in Spanish]. Med Clin (Barc) 2004; 122: 269-74
12. Taniyama Y, Ito H, Iwakura K, et al. Effects of intracoronary injection of verapamil and nicorandil on microcirculation and left ventricular function inpatients with reperfused myocardial infarction [abstract]. Circulation 1995; 92: 177
13. Sheiban I, Tonni S, Chizzoni A, et al. Recovery of left ventricular function following early reperfusion in acute myocardial infarction: a potential role for the calcium antagonist nisoldipine. Cardiovasc Drugs Ther 1997; 11: 5-16
14. Barsotti A, Napoli P. Trimetazidine and cardioprotection during ischemia-reperfusion. Ital Heart J 2004; 5 Suppl. 2: 29-36S
15. Donato M, Gelpi RJ. Adenosine and cardioprotection during reperfusion: an overview. Mol Cell Biochem 2003; 251: 153-9
16. Siegfried MR, Erhardt J, Rider T, et al. Cardioprotection and attenuation of endothelial dysfunction by organic nitric oxide donors in myocardial ischemia-reperfusion. J Pharmacol Exp Ther 1992; 260: 668-75
17. + exchange inhibition in ischemic, reperfused porcine hearts. Circulation 1995; 92: 912-7
18. Przyklenk K. Pharmacologic treatment of the stunned myocardium: the concepts and the challenges. Coron Artery Dis 2001; 12: 363-9
19. Pernow J, Wang QD. Endothelin in myocardial ischaemia and reperfusion. Cardiovasc Res 1997; 33: 518-26
20. Pollesello P, Mebazaa A. ATP-dependent potassium channels as a key target for the treatment of myocardial and vascular dysfunction. Curr Opin Crit Care 2004; 10: 436-41
21. Mannhold R. K-ATP channel openers: structure-activity relationships and therapeutic potential. Med Res Rev 2004; 24: 213-66
22. Auchampach JA, Maruyama M, Cavero I, et al. Pharmacological evidence for a role of ATP-dependent potassium channels in myocardial stunning. Circulation 1992; 86: 311-9
23. Innes CA, Wagstaff AJ. Levosimendan: a review of its use in the management of acute decompensated heart failure. Drugs 2003; 63 (23): 2651-71
24. Nieminen MS, Bohm M, Cowie MR, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology: ESC Committee for Practice Guideline (CPG). Eur Heart J 2005 Feb; 26 (4): 384-416
25. Rosevear PR, Finley N. Molecular mechanism of levosimendan action: an update. J Mol Cell Cardiol 2003; 35: 1011-5
26. 2+ current via phosphodiesterase-3 inhibition in human cardiac myocytes. Eur J Pharmacol 2002; 435 (1): 27-33
27. + channel in rat ventricular cells. J Pharmacol Exp Ther 1997; 283: 375-83
28. Gruhn N, Nielsen-Kudsk JE, Theilgaard S, et al. Coronary vasorelaxant effect of levosimendan, a new inodilatador with calcium-sensitizing properties. J Cardiovasc Pharmacol 1998; 31: 741-9
29. Nieminen MS, Akkila J, Hasenfuss G, et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 2000; 36: 1903-12
30. Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002; 360: 196-202
31. Labriola C, Siro Brigiani M, Carrata F, et al. Hemodynamic effects of levosimendan in patients with low-output heart failure after cardiac surgery. Int J Clin Pharmacol Ther 2004; 42: 204-11
32. Benlolo S, Lefoll C, Katchatouryan V, et al. Successful use of levosimendan in a patient with peripartum cardiomyopathy. Anesth Analg 2004; 98: 822-4
33. García-González MJ, Domínguez-Rodríguez A, Ferrer-Hita JJ. Utility of levosimendan, a new calcium sensitizing agent, in the treatment of cardiogenic shock due to myocardial stunning in patients with ST elevation myocardial infarction: a series of cases. J Clin Pharmacol 2005; 45: 704-8
34. Halestrap AP, Clarke SJ, Javadov SA. Mitochondrial permeability transition pore opening during myocardial reperfusion: a target for cardioprotection. Cardiovasc Res 2004; 61: 372-85
35. McBride BF, White CM. Levosimendan: implications for clinicians. J Clin Pharmacol 2003; 43: 1071-81
36. Parissis JT, Adamopoulos S, Antoniades CH, et al. Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. Am J Cardiol 2004; 93: 1309-12
37. Kersten JR, Montgomery MW, Pagel PS, et al. Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels. Anesth Analg 2000; 90: 5-11
38. Jamali IN, Kersten JR, Pagel PS, et al. Intracoronary levosimendan enhances contractile function of stunned myocardium. Anesth Analg 1997; 85: 23-9
39. Du-Toit EF, Muller CA, McCarthy J, et al. Levosimendan: effects of a calcium sensitizer on function and arrhythmias and cyclic nucleotide levels during ischemia/reperfusion in the Langendorff-perfused guinea pigs heart. J Pharmacol Exp Ther 1999; 290: 505-14
40. Cuesta Teŕan MT, Martińez de la Gándara M, Martińez Vallejo M. Nuevos principios activos: Levosimendan. Ministerio de Sanidad y Consuma. Informacioń Terapéutica del Sistema Nacional de Salud 2002; 26 (6): 161-2
41. Swedish Medical Products Agency. Simdax® (levosimendan): summary of the product characteristics [online]. Available from URL: http://www.mpa.se/ spc_pil/pdf/enhumspc/Simdax%20ENG.pdf [Accessed 2004 Sep 29]
42. Moiseyev VS, Poder P, Andrejevs N, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction: a randomized, placebo-controlled, double-blind study (RUSSLAND). Eur Heart J 2002; 23: 1422-32
43. Slawsky MT, Colucci WS, Gottlieb SS, et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure: study investigators. Circulation 2000; 102: 2222-7
44. Cleland JGF, Ghosh J, Freemantle N, et al. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-LIPIDS and cardiac resynchronisation therapy in heart failure. Eur J Heart Fail 2004; 6: 501-8
45. Cleland JGF, Freemantle N, Coletta AP, et al. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE - II, SURVIVE, and PROACTIVE. Eur J Heart Fail 2006; 8: 105-10
46. Sonntag S, Sundberg S, Lehtonen LA, et al. The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia. J Am Coll Cardiol 2004; 43: 2177-82
47. Lehmann A, Lang J, Boldt J, et al. Levosimendan in patients with cardiogenic shock undergoing surgical revascularization: a case series. Med Sci Monit 2004; 10: 89-93